Here are three things to know.
- Vyxeos is a fixed-combination therapy containing two chemotherapy drugs.
- The drug is intended to treat adults with two types of high-risk AML.
- In a recent clinical trial, patients taking Vyxeos had a median overall survival of 9.56 months, compared to 5.95 months for those receiving the two chemotherapy drugs separately.
More articles on supply chain:
Device recalls fall in Q2, drug recalls rise: 10 report findings
Woman sues CVS over generic drug co-pay ‘clawbacks’
Fujifilm recalls duodenoscopes over infection risk
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
